Highlights

  • Argenica Therapeutics shares rose 1.48% on 21 May 2026 following a regulatory update.
  • The company completed an FDA-requested Mouse Lymphoma Assay for ARG-007.
  • Results showed no evidence of gene mutation or chromosomal aberrations.
  • Two of the three FDA-requested studies have now been completed.
  • The final hERG cardiac safety assay is currently underway.
  • Argenica aims to submit a comprehensive FDA clinical hold response after the remaining study is completed.

Argenica Therapeutics Ltd (ASX:AGN) shares increased 1.48% to AUD 0.14 during the afternoon session on 21 May 2026 after the biotechnology company announced favourable results from a key FDA-requested safety study linked to its lead drug candidate, ARG-007. Despite today’s gain, the stock remains down 82.66% over the past year.

The latest update relates to the company’s ongoing efforts to address the United States Food and Drug Administration (FDA) clinical hold placed on its Investigational New Drug (IND) application for ARG-007, a neuroprotective therapy being developed for stroke and acute neurological conditions.

According to the company, the newly completed in vitro Mouse Lymphoma Assay (MLA) produced no evidence of gene mutation or chromosomal damage, directly addressing one of the FDA’s requested genotoxicity requirements.

Company Overview

Argenica Therapeutics is a clinical-stage biotechnology company focused on developing therapies aimed at reducing brain tissue damage following stroke and other neurological injuries.

Its lead therapeutic candidate, ARG-007, is designed to protect vulnerable brain tissue by limiting secondary cell death after ischemic events such as stroke. The company is seeking to advance ARG-007 through clinical development pathways in both the United States and Australia.

Argenica’s development strategy is centred on addressing unmet medical needs in acute neurology, particularly in moderate to severe stroke patients where treatment Options remain limited.

The company has been progressing regulatory and safety-related studies required to support future human Clinical Trials for ARG-007.

FDA-Requested Genotoxicity Study Successfully Completed

The latest announcement focused on the successful completion of a Good Laboratory Practice (GLP)-compliant Mouse Lymphoma Assay requested by the FDA as part of the company’s IND clinical hold response.

The FDA had previously informed Argenica that an earlier bacterial genotoxicity test, known as the Ames assay, was considered inadequate due to technical interference caused by the characteristics of ARG-007.

As part of its clinical hold response, the FDA specifically requested that the company complete a follow-up mammalian cell gene mutation assay, identifying the mouse lymphoma thymidine kinase assay as an acceptable approach.

Argenica has now completed that study under full GLP conditions, with the company reporting that ARG-007 showed no signs of causing gene mutations or chromosomal aberrations under any tested condition.

The company further stated that none of the tested concentrations exceeded the regulatory threshold required for a positive genotoxicity finding.

According to Argenica, the outcome supports a favourable genotoxicity profile for ARG-007 and directly addresses the FDA’s concerns regarding the mammalian cell mutation assessment component of the clinical hold.

Study Conducted Under International Regulatory Standards

The MLA study was conducted by Labcorp Early Development Laboratories in Huntingdon, United Kingdom, under internationally recognised GLP standards.

The assay was completed in compliance with OECD Guideline 490 and ICH S2(R1), which are internationally accepted frameworks for genotoxicity testing.

The study assessed whether ARG-007 could induce forward mutation at the thymidine kinase locus in mouse lymphoma L5178Y cells.

Testing was conducted both in the presence and absence of a rat liver metabolising system known as S-9, with treatment periods spanning both three-hour and 24-hour exposure durations.

The study examined concentrations up to the highest analysable levels, with upper limits influenced by compound precipitation thresholds.

A preliminary cytotoxicity experiment was also conducted to establish suitable concentration ranges for the mutation analysis phase.

Across all test conditions, the company reported that mutant frequency levels remained below the Global Evaluation Factor threshold of 126 mutants per one million viable cells — the benchmark used to determine a positive result.

Argenica also stated that statistical analysis showed no dose-dependent increase in mutation frequency attributable to ARG-007.

Understanding Why the FDA Requested the MLA

The company provided additional background explaining why the FDA requested the Mouse Lymphoma Assay despite earlier testing already being completed.

Before investigational drugs can proceed into human clinical trials, regulators generally require multiple studies evaluating whether a therapy has the potential to damage DNA.

Argenica had already completed two previous genotoxicity assessments for ARG-007, both of which showed no evidence of DNA damage.

However, the third bacterial-based DNA test produced inconclusive findings. The company explained that this outcome was not linked to a safety issue, but instead related to ARG-007’s cell-penetrating properties interfering with the bacterial system used in the assay.

International regulatory guidelines provide for alternative mammalian cell testing in these situations, which led to the FDA directing Argenica to conduct the MLA.

The company noted that mammalian cells used in the assay are considered more biologically relevant to human systems and are more tolerant of cationic peptide compounds such as ARG-007.

Argenica also stated that the MLA simultaneously evaluates both gene mutations and chromosomal aberrations, making it a comprehensive assessment tool.

Importantly, the FDA had specifically identified the MLA as an acceptable follow-up study for the IND application.

Two of Three FDA Requirements Now Complete

The company confirmed that the MLA represents the second of three FDA-requested studies linked to the clinical hold process.

Argenica had previously completed the first required study involving interaction testing with the clot-dissolving drug Tenecteplase (TNK), reporting positive results in December 2025.

The third and final required study — the GLP hERG cardiac safety assay — is currently in progress.

This assay evaluates whether ARG-007 affects cardiac potassium channels associated with arrhythmia risk, an important component of drug safety assessment.

Once the hERG study is completed, Argenica intends to assemble a comprehensive response package addressing all FDA concerns associated with the IND clinical hold.

The submission will also include an updated Phase 2b clinical trial protocol focused on moderate to severe stroke patients.

Under FDA procedures, the regulator has 30 days from receiving a complete clinical hold response to determine whether the hold can be lifted.

If approved, the IND reinstatement would allow Argenica to commence its planned Phase 2b trial for ARG-007 in the United States.

Australian Trial Preparations Also Progressing

Alongside its US regulatory work, Argenica is also preparing approvals required to establish clinical trial sites in Australia.

The company stated that it is progressing Human Research Ethics Committee (HREC) submissions as part of preparations for the proposed Phase 2b study.

This dual-track regulatory strategy appears aimed at supporting broader clinical development opportunities for ARG-007 across multiple jurisdictions.

The company’s ongoing focus remains on advancing the therapy into human clinical trials following completion of the FDA hold response process.

Management Commentary Reflects Progress Toward FDA Response

Managing Director Dr Liz Dallimore described the successful completion of the MLA as an important step in addressing the FDA’s clinical hold requirements.

According to management, the latest study directly addressed the genotoxicity concerns identified by the regulator and further supports the safety profile of ARG-007.

Dr Dallimore also noted that with two of the three required studies now complete and the hERG assay progressing, the company is entering the final stages of preparing the broader safety package required for submission to the FDA.

Investors appear to be monitoring whether completion of the remaining cardiac safety study could position the company to move closer toward restarting the IND approval process.

What Investors May Be Watching Next

The market’s reaction on Thursday suggests investors responded favourably to continued progress surrounding the FDA clinical hold pathway for ARG-007.

The next major milestone for the company is likely to be completion of the hERG cardiac safety assay, which remains the final outstanding FDA-requested study.

Investors may also continue watching for updates regarding submission timing of the comprehensive clinical hold response package and any subsequent FDA feedback.

Given the significance of IND approval for progression into Phase 2b trials in the United States, regulatory developments surrounding ARG-007 are likely to remain a central focus for the market.

The company’s preparations for Australian trial approvals may also remain relevant as Argenica advances its broader clinical development strategy.